Effectiveness of adding vildagliptin to the treatment of diabetic patients nonresponsive to the combination of metformin and a sulphonylurea;Eficácia da adição de vildagliptina ao tratamento de pacientes diabéticos não responsivos à combinação de metformina e uma sulfonilureia

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 55, Issue 4, 2011, Pages 260-265

  Vilar, Lucio ^a,b   Gusmão, Amaro ^a,b   Albuquerque, José Luciano ^b   Pontes, Lisete ^b   Montenegro, Larissa ^b   Pontes, Soraya ^b   Ibiapina, George Robson ^b   Cunha, Rodrigo Andrade ^b   Alves, Gercivan Dos Santos ^b   Canadas, Viviane ^b   Ferreira, Vera Maria Santos G ^b   Nóbrega, Lucia Helena Coelho ^c   de Lima, Josivan Gomes ^c  

^a Center for Diabetes and Endocrinology of Pernambuco   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c Center for Endocrinology of Natal   (Brazil)

Author keywords

Metformin; Sulphonylurea; Triple oral therapy; Vildagliptin

Indexed keywords

ADAMANTANE; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; METFORMIN; NITRILE; PYRROLIDINE DERIVATIVE; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; DIET RESTRICTION; DRUG COMBINATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ADAMANTANE; ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES; SULFONYLUREA COMPOUNDS; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 79960471604     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302011000400004     Document Type: Article

References (31)

1. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-95.
2. Mizuno CS, Chittiboyina AG, Kurtz TW, Pershadsingh HA, Avery MA. Type 2 diabetes and oral antihyperglycemic drugs. Curr Med Chem. 2008;15(1):61-74.
3. Wajchenberg BL. Beta -cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187-218.
4. Freeman JS. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleve Clin J Med. 2009;76 Suppl 5:S12-9.
5. McGill JB. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgrad Med. 2009;121(1):46-58.
6. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide- 1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705.
7. Mattheus DR, Ahmed S, Lyra R, Vilar L. In: Vilar L, et al., editors. Endocrinologia clínica, 4th ed. Rio de Janeiro: Guanabara Koogan; 2009. p. 622-41.
8. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al.; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
9. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-59. Erratum in: Endocr Pract. 2009;15(7):768-70.
10. Vilar L, Canadas V, Arruda MJ, Arahata C, Agra R, Pontes L, et al. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes. Arq Bras Endocrinol Metabol. 2010;54(3):311-8.
11. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2010;30(5):463-84.
12. Rosenstock J, Fitchet M. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes. Int J Clin Pract Suppl. 2008;(159):15-23.
13. Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med. 2009;76 Suppl 5:S28-38.
14. Mavian AA, Miller S, Henry RR. Managing type 2 diabetes: balancing HbA1c and body weight. Postgrad Med. 2010;122(3):106-17.
15. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29(8):1963-72.
16. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005;65(3):385-411.
17. Kleppinger EL, Helms K. The role of vildagliptin in the management of type 2 diabetes mellitus. Ann Pharmacother. 2007;41(5):824-32.
18. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92(4):1249-55.
19. Purkayastha D, Baron M. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study. Diabetes Obes Metab. 2009;11(10):978-86.
20. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, et al. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes Metab. 2010;12(9):780-9.
21. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27(3):318-26.
22. Bell DS, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract. 2002;8(4):271-5.
23. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29(3):554-9.
24. Schweizer A, Dejager S, Foley JE, Kothny W. Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. Vasc Health Risk Manag. 2011;7:49-57.
25. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-8.
26. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89.
27. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, et al.; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125-35.
28. Kahn SE, Zinman B, Lachin JM, Herman WH, Holman RR, Kravitz BG, et al.; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845-51.
29. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-71.[Erratum, N Engl J Med. 2007;357(1):100.]
30. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298(10):1189-95.
31. Retnakaran R, Zinman B. Thiazolidinediones and clinical outcomes in type 2 diabetes. Lancet. 2009;373(9681):2088-90.